Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALIBER: LINX vs Double-Dose PPI for GERD
NCT02505945Phase 4Completed
- Sponsor
- Torax Medical
- Start
- Jun 2015
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Torax Medical. Primary endpoint: Elimination of Moderate-severe Regurgitation at 6 months. Started Jun 2015; status: completed.
Beyond the preview
Go deeper on NCT02505945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505945.